Evaluation of Matrix Metalloproteinase‐1 and Tissue Inhibitor of Metalloproteinase‐1 Levels in Gingival Fibroblasts of Cyclosporin A‐Treated Patients

Publisher Website
Google Scholar
Abstract
Background: Cyclosporin A (CsA) is a potent immunosuppressant used to prevent organ transplant rejection and to treat various autoimmune diseases. CsA‐induced gingival overgrowth (CsA GO) is the most widely seen side effect of this drug; its pathogenesis is not completely understood. The aim of this study was to identify and compare matrix metalloproteinase‐1 (MMP‐1) and tissue inhibitor of metalloproteinase‐1 (TIMP‐1) levels in gingival fibroblast cultures of tissues derived from renal transplant patients receiving CsA and exhibiting gingival overgrowth and from periodontally healthy control subjects.Methods: Gingival overgrowth samples were obtained from patients undergoing therapy with CsA, and control tissues were obtained from systemically healthy donors. Gingival fibroblasts were grown using explant cultures. Three different study groups were identified: 1) CsA GO fibroblast culture; 2) CsA‐treated healthy gingival fibroblast culture (H+CsA); and 3) healthy gingival fibroblast culture (H). The levels of MMP‐1 and TIMP‐1 in these groups of gingival fibroblasts were analyzed by enzymelinked immunoabsorbent assay (ELISA).Results: The levels of TIMP‐1 were significantly lower in CsA GO than H (P P ‐0.505). The ratio of MMP‐1 to TIMP‐1 was significantly higher in CsA GO than H (P Conclusions: The results of this study indicate that CsA therapy does not have a significant effect on MMP‐1 levels. However, low TIMP‐1 levels can be an important factor in the pathogenesis of CsA GO, since the balance between MMP‐1 and TIMP‐1 levels was changed by CsA. J Periodontol 2002;73:1273‐1278.